Compared to the numerous broad screens for oncogene mutations in adult cancers, very few have been performed in pediatric solid tumors. To identify novel mutations and potential therapeutic targets in pediatric cancers, we performed a high-throughput Sequenom-based analysis in large sets of several major pediatric solid cancers, including neuroblastoma (NB), Ewing sarcoma (ES), rhabdomyosarcoma (RMS), and desmoplastic small round cell tumor (DSRCT).
profiling can identify a subset of pediatric solid tumor patients as candidates for kinase inhibitors or RAS-targeted therapies.
Statement of translational relevance
To identify novel mutations and potential therapeutic targets in pediatric cancers, we performed a high-throughput screen to interrogate 275 recurrent mutation sites across 29 cancer genes in 192 neuroblastomas (NB), 75 Ewing sarcomas (ES), 89 rhabdomyosarcomas (RMS), and 24 desmoplastic small round cell tumors (DSRCT). In embryonal RMS (ERMS), ES, and NB, we identified novel occurrences of several oncogene mutations recognized as drivers in other cancers, including for the first time PIK3CA and CTNNB1 (beta-catenin) mutations in ERMS. Overall, NB and ERMS contain significant subsets of cases with non-overlapping mutated genes in growth signaling pathways. In particular, a substantial minority of ERMS show mutations in the RAS pathway. As more agents inhibiting mutated oncoproteins and their associated downstream signaling pathways become available, mutational genotyping of pediatric solid tumors such as RMS will serve as an important tool for identifying targeted therapy options for individual patients. The Sequenom MassARRAY technology utilizes a mass spectrometry-based genotyping approach which allows for more sensitive mutational analysis compared to traditional Sanger sequencing. (8) This platform also performs well using DNA extracted from archived paraffin embedded material. Furthermore, highly multiplexed PCR assays allow for efficient highthroughput screening of large tumor sample sets. (9) In order to identify novel mutations in pediatric tumors, we utilized the Sequenom MassARRAY platform to perform a high-throughput sequencing analysis interrogating 275 point mutations across 29 oncogenes in large sample sets of four tumor types: NB, ES, RMS, and DSRCT. In 6 their susceptibility as a therapeutic target and mutation frequency. Furthermore, an extended list of BRAF and PTPN11 mutations was generated based on known germline mutations in RAS/MAPK syndromes (10, 11). Insertion and deletion type mutations were not included. A total of 275 point mutations (Supplemental Table S2 ) across 29 genes were selected for interrogation ( Table 1) . Input sequence files for assay design were generated by the MSKCC Bioinformatics Core Facility.
Sequenom Based DNA Sequencing:
For these assays we used the MassARRAY system (Sequenom), which is based on matrixassisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).
Genotyping by this method relies on the principle that mutant and wild-type alleles for a given point mutation produce single-allele base extension reaction products of a mass that is specific to the sequence of the product. Mutation calls are based on the mass differences between the wild-type product and the mutant products as resolved by MALDI-TOF MS. Amplification and extension primers were designed using Sequenom Assay Designer v3.1 software to target the curated list of mutations. Amplification primers were designed with a 10mer tag sequence to increase their mass so that they fall outside the range of detection of the MALDI-TOF MS. The sequences of primers are shown in Supplemental Table S3 . SpectroCHIPs were analyzed using the Autoflex MALDI-TOF MS (Bruker AXS, Madison, WI), and the spectra were processed using SpectroACQUIRE software (Sequenom) in real time. Genotype calls are automatically generated using complex mathematical algorithms according to the peak heights, noise-to-peak-height ratio, area under the curve, and anchoring of the peaks. Whole Genome Amplification (WGA):
WGA was performed on 62 RMS samples and 74 EWS samples for sequencing of FGFR4 and CTNNB1. For frozen tissue, the Repli-G Midi (Qiagen, Valencia, CA) was used to amplify 100 ng of genomic DNA. WGA DNA was assessed by Picogreen quantification followed by PCR amplification with two control amplicons. For FFPE samples, The Sigma GenomePlex (Sigma Aldrich) was used to amplify 100 ng of genomic DNA. WGA DNA was assessed by Picogreen quantification followed by PCR amplification with two control amplicons.
PCR Amplification and DNA Sequencing of WGA Samples:
All exons of FGFR4 and exon 3 of CTNNB1 were amplified as amplicons of 500 bp or less, covering the exonic regions plus at least 50 bp of intronic sequences (Supplemental Table S4 ). 
Results:
Mutations were identified by Sequenom analysis in 13% (25/192) identified by Sequenom analysis and the remainder identified by direct sequencing of FGFR4 (described below). Mutations were observed in 3.5% (1/29) of alveolar RMS (ARMS) samples.
The majority of NB mutations were activating ALK mutations (Table 3) , accounting for 10.4% of the tumor samples, a proportion consistent with previous reports (15) . The remainder of NB mutations involved BRAF, RAS, and MAP2K1 genes and were not seen in samples harboring ALK mutations.
Research. PIK3CA mutations were identified in 5% (3/60) of ERMS cases, but were not seen in any other tumor type in our screen (Figure 1) . Two of the 3 mutations were in the helical domain of the gene (E542K and E545K). The other mutation was located in the kinase domain (H1047R).
CTNNB1 mutations were identified in 1.3% (1/75) of ES samples, and 3.3% (2/60) of ERMS samples ( Figure 2) . One of the ERMS samples contained both an NRAS and a CTNNB1 gene mutation.
A PTPN11 mutation was identified in 1.7% (1/60) ERMS samples. The tumor was from a patient diagnosed with Neurofibromatosis type 1. Sequencing of normal tissue from this patient confirmed the PTPN11 mutation to be somatic. confirmed the FGFR4 mutations to be somatic in both cases. Of the remaining 2 FGFR4-mutated samples, one lacked corresponding normal tissue and the other was a cell line (RMS 559). Additional CTNNB1 mutations, aside from those detected by the Sequenom assay, were not found in any of the RMS or ES samples.
Discussion:
Multiple large scale cancer genomics efforts are underway to better characterize tumors and to help identify new therapeutic targets but few of these include pediatric solid tumors. Several genes have been examined for mutations in various pediatric tumor types (5, (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) ) but the present study represents the most expansive "hotspot" mutation profiling for these tumor types that has been reported to date. Here, we used a mass spectrometry-based platform to survey recurrent point mutations in 29 cancer genes in 380 cases of 4 major pediatric solid cancers.
The frequency of mutations found in our study was lower than in most adult onset carcinomas.
Given the embryonal origin of these pediatric cancers, it is also possible that different genes are recurrently mutated in these tumor types. More comprehensive approaches such as whole exome sequencing would be needed to identify such mutations. However, a significant proportion of ERMS tumor samples were found to harbor various targetable mutations from our focused screen (Figure 3 The ERMS cell line SMS-CTR was found to have an HRAS Q61K mutation. One of the 29 ARMS samples was found to have a RAS mutation. It was the sole mutation found in our cohort of ARMS samples. Our mutation data suggests that overall, RAS mutations are more typical of translocation-negative RMS but this difference may require a larger sample set to confirm statistically.
To our knowledge, RAS mutations have not been described in NB or ES. Whereas two studies have reported completely negative results (16, 19) , another study described a rare codon 59 NRAS mutation in a NB cell line, which was not seen when the original tumor DNA was sporadic RMS cases. However, we identified only one PTPN11 and one BRAF mutation in our survey of RMS samples. 
